A rundown of recent Trump administration vaccine policy changes
The Trump administration continued to reshape U.S. health policy in recent days with several moves that could change what vaccines people can get to protect themselves from common illnesses.
Some of the changes are immediate, others are still being discussed, and Health Secretary Robert F. Kennedy Jr. must still sign off on some.
Doctors' groups have expressed alarm at the moves made by Kennedy, a longtime anti-vaccine activist, and his appointees, who at times have ignored well-established science. Nearly 80 medical groups, including the American Medical Association, issued a statement backing vaccines against common respiratory ailments as 'among the best tools to protect the public.'
'We come together as physicians from every corner of medicine to reaffirm our commitment to these lifesaving vaccines,' the groups wrote.
Here's what to know about some of the recent vaccine policy changes:
Flu shots and thimerosal
On Thursday, a vaccine advisory group handpicked by Kennedy recommended that just about every American get a flu shot this fall.
But the group also said people should avoid shots containing thimerosal, a preservative used only in large multi-dose vials that has been proven to be safe. The ingredient isn't used in single-dose flu shots, the type of syringe used for about 95% of U.S. flu shots last season.
Status: Kennedy must sign off on the recommendations. Read more AP coverage here.
How to get a COVID-19 shot
Universal access to updated COVID-19 shots for the fall remains unclear, even after Kennedy's vaccine advisers were shown data showing how well the vaccines are working.
Kennedy changed CDC guidance last month, saying the shots are no longer recommended for healthy children and pregnant women — even though doctors groups disagree. And the Food and Drug Administration has moved to limit COVID-19 vaccinations among healthy people under age 65.
Expanded warnings on COVID-19 vaccine labels
At the request of the FDA, makers of the two leading COVID-19 vaccines on Wednesday expanded existing warnings about a rare heart side effect mainly seen in young men.
Prescribing information from both Pfizer and Moderna had already advised doctors about rare cases of myocarditis, a type of heart inflammation that is usually mild. The FDA had asked the drugmakers to add more detail about the problem and to cover a larger group of patients.
Status: Labels are being updated now. Read more AP coverage here.
Changes considered for the childhood vaccine schedule
On Wednesday, Kennedy's vaccine advisers said they would be evaluating the 'cumulative effect' of the children's vaccine schedule — the list of immunizations given at different times throughout childhood.
The announcement reflected vaccine skeptics' messaging: that too many shots may overwhelm kids' immune systems. Scientists say those claims have been repeatedly investigated with no signs of concern.
The American Academy of Pediatrics said it would continue publishing its own vaccine schedule for children but now will do so independently of the government advisory panel, calling it 'no longer a credible process.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Senate bill's Medicaid cuts draw some GOP angst
The Senate's deep cuts to Medicaid in the tax and spending megabill are setting off alarm bells among some Republicans, complicating leadership's effort to get the legislation passed by July 4. It seeks to clamp down on two tactics states use to boost Medicaid funding to hospitals: state-directed payments and Medicaid provider taxes. The restrictions are a major concern for rural hospitals, a key constituency for senators. Republicans have set an ambitious July 4 deadline to pass the bill and send it to President Trump to be signed into law. Sen. Josh Hawley (R-Mo.), who has been warning his colleagues about making cuts to Medicaid for weeks, said the changes took him by surprise. 'I had no idea that they were going to completely scrap the House framework with this. I mean, this totally caught me by surprise. And I've talked to other senators, and that's what I've heard consistently from everybody I've talked to, that no one was expecting this entirely new framework,' Hawley told reporters Tuesday. States impose taxes on providers to boost their federal Medicaid contributions, which they then direct back to hospitals in the form of higher reimbursements. Critics argue it's a scheme for states to get more federal funding without spending any of their own money. But provider taxes have become ingrained into states' Medicaid financing systems. States and provider groups say the taxes provide a steady source of financing for hospitals that operate on thin margins and would otherwise face closure. 'The draconian Medicaid cuts contained in the Senate bill would devastate health care access for millions of Americans and hollow out the vital role essential hospitals play in their communities,' said Bruce Siegel, president and CEO of America's Essential Hospitals, an organization that represents hospitals that serve low-income patients. The legislation would effectively cap provider taxes at 3.5 percent by 2031, down from the current 6 percent, but only for the states that expanded Medicaid under the Affordable Care Act. The cap would be phased in by lowering it 0.5 percent annually, starting in 2027. Nonexpansion states would be prohibited from imposing new taxes, but as was true in the House-passed version, their rates would be frozen at current levels. The lower cap would not apply to nursing homes or intermediate care facilities. All states except for Alaska finance part of their share of Medicaid funding through health care provider taxes, and 38 states have at least one provider tax that exceeds 5.5 percent. When asked if his concerns were enough to make him vote against the bill if it were brought to the floor as written, Hawley hedged. 'It needs a lot of work, so I would say maybe we could, I guess, try to fix it on the floor, but it'd be better to do it beforehand,' he told reporters. Republicans can afford to lose only three votes in the Senate and still pass their bill if Democrats remain united in opposition. Sen. Jim Justice ( said he was also surprised by the Senate's change. If provider tax changes are on the table, he said he wants leadership to keep the House version. Justice wouldn't say how he would vote if the provision was left unchanged but expressed some unease about the July 4 deadline. 'I promise you, I won't rubber-stamp anything,' Justice said. 'I want this thing to come out and come out quickly, but when it really boils right down to it, you may have to hold your nose on some things that you just absolutely don't like because we can't like everything.' Similarly, Sen. Bill Cassidy (R-La.) indicated he would also prefer the House-passed freeze on provider taxes but was still analyzing the impact on his state. Louisiana expanded Medicaid in 2016. Senate Republican leaders huddled with members Tuesday during a closed-door caucus lunch to talk through the details of the bill. Speaking to reporters afterward, Majority Leader John Thune (R-S.D.) said leadership was listening to members' concerns, especially about provider taxes. 'We think [the changes] rebalance the program in a way that provides the right incentives to cover the people who are supposed to be covered,' Thune said. 'We continue to hear from members specifically on components or pieces of the bill they want to see modified or changed, and we are working through that.' Members were also briefed by Centers for Medicare and Medicaid Services Administrator Mehmet Oz, who downplayed the impact of a lower provider tax cap. 'We do not believe that addressing the provider tax effort is going to influence the ability of hospitals to stay viable,' Oz told reporters. Without weighing in on the exact details, Oz said some changes to provider taxes and state-directed payments should be included. 'The framework of addressing the legalized money laundering with state-directed payments and provider taxes must be in this bill, it should be in this bill,' Oz said. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Epoch Times
11 hours ago
- Epoch Times
Remedies for ‘Razor-Blade Throat,' a Symptom of the Emerging Nimbus COVID Variant
A new COVID-19 subvariant, dubbed 'Nimbus,' has rapidly gained prominence across the United States to become the dominant strain in recent weeks, according to health officials. They are warning of a new twist to COVID-19 symptoms: a severe sore throat often described as 'razor blade throat' with pain that is more severe than typical coronavirus symptoms.
USA Today
15 hours ago
- USA Today
Texas politicians lead effort to study a psychedelic drug. What is ibogaine?
Ibogaine is illegal in the U.S., but growing evidence shows its promise treating the effects of traumatic brain injury and substance use disorder. A once obscure traditional psychedelic plant from Africa has made headlines recently as Texas pushes for more research and a prominent Republican wrote a vigorous endorsement of its possible use for the treatment of addiction and for veterans experiencing mental health issues. Ibogaine is illegal for use in the United States, but a growing body of evidence has shown its promise treating the effects of traumatic brain injury and substance use disorder. Earlier in June, Texas Gov. Greg Abbott signed legislation to allocate $50 million for clinical trials approved by the Food and Drug Administration to study ibogaine. Texas is set to lead research into the drug's benefits treating mental health issues and addiction as a potential medication. Former Energy Secretary Rick Perry, also a former Texas governor, wrote a June 27 Washington Post op-ed supporting ibogaine research and criticizing the legacy of the war on drugs, started by President Richard Nixon and touted by President Ronald Reagan. Perry said he has 'come to realize just how wrong that narrative was.' 'That fear-based messaging kept us from exploring treatments that could have saved countless lives,' Perry wrote. Perry and a growing number of conservatives have argued ibogaine could be one of those treatments. Here's what to know about the drug. What is ibogaine? Ibogaine derives from the root of the iboga plant native to western-central Africa. It's been used in ceremonial rituals for centuries. It has hallucinogenic properties. The United States outlawed ibogaine in 1967 along with other psychotropic drugs. The Controlled Substances Act of 1970 placed it as a schedule I hallucinogenic drug, along with marijuana. Ibogaine's classification prevented researchers from studying its effects. But unlike other schedule 1 drugs such as heroin, ibogaine has anti-addictive properties. There are risks since ibogaine can delay the body's normal electrical signals that control heart rhythm, which could lead to death. Other countries, such as Mexico, have allowed its use. American veterans and others have traveled to smaller, clandestine clinics for treatment to deal with depression, post-traumatic stress disorder and addiction. Many clinics are along the border and around cities such as Tijuana. Why is it in the news? At the state and federal level, there is growing interest in studying psychedelic drugs to treat veterans and others. Texas passed legislation earlier in June to study the drug with a public university alongside a company and hospital, Abbott's office said. Dr. Marty Makary, the FDA commissioner, has said expanding research on psychedelic drugs is a top priority for the Trump administration. In his op-ed, Perry cited the experiences of Morgan and Marcus Luttrell, twin combat veterans, who used ibogaine for recovery. Morgan Luttrell is now a Republican congressman from Texas who has advocated for ibogaine and other psychedelic drugs as treatment options. In January 2025, Perry and W. Bryan Hubbard, an advocate for ibogaine treatment, appeared on Joe Rogan's podcast to discuss ibogaine's benefits as a plant-based medicine. Hubbard led a Kentucky task force that sought to use opioid settlement funds to research ibogaine's effects to treat addiction, but the initiative failed to gain support in the state. Hubbard and Perry eventually launched the Texas Ibogaine Initiative, which helped spur the state funding. What has research shown? Research, such as a Stanford University study of 30 male combat veterans, has shown ibogaine's promise. Coupled with magnesium sulfate to address heart effects, ibogaine appeared to reduce symptoms of PTSD, anxiety and depression, and improve cognitive function from traumatic brain injury, according to the study, published in 2024 in the eminent journal Nature Medicine. Other studies have shown benefits treating addiction and depression. What do critics say? One issue with ibogaine is the ability to produce it, because it is derived from a rare plant and has mostly been used for ceremonial purposes. There is research to help innovate its safe production, but it could be difficult for the drug to be more widely available, as researchers at the University of California, Davis, Institute for Psychedelics and Neurotherapeutics have said. And while it's shown benefits with combat veterans, questions remain on its efficacy among randomized participants. With Texas' research, ibogaine could get closer to FDA approval for its use as a medication.
